Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension

被引:59
作者
Mahmud, A [1 ]
Feely, J [1 ]
机构
[1] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Dublin 8, Ireland
关键词
angiotensin II receptor antagonists; arterial wave reflection; pulse pressure amplification; valsartan; arterial compliance;
D O I
10.1038/sj.jhh.1001053
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective: Angiotensin-converting enzyme (ACE) inhibitors have beneficial effects on arterial compliance and distensibility and favourably modify the arterial pressure waveform in hypertensive patients, The objective of our study was to explore the possible effects of adding an ATII AT(1) receptor antagonist to an ACE inhibitor on augmentation pressure, a measure of arterial stiffness, and pulse pressure amplification in patients with poorly controlled essential hypertension, Design and methods: We studied a group of 18 patients with poorly controlled hypertension, despite at least three antihypertensive drugs including an ACE inhibitor, before, at 2 h and 2 weeks following the administration of 80 mg of valsartan, an ATII AT(1) receptor antagonist. Haemodynamic responses were measured by cuff sphygmomanometry, arterial pulse-wave analysis and the pulse pressure gradient was calculated as the difference between the brachial pulse pressure (cuff sphygmomanometry) and derived aortic pulse pressure (arterial pulse wave analysis), Results: Blood pressure decreased significantly (P < 0.001) and the effect was more pronounced on central (aortic) pulse pressure than peripheral (brachial) pulse pressure. The pulse pressure amplification increased significantly (from 8 +/- 3 at baseline vs 12 +/- 7 at 2 h to 14 +/- 5 mm Hg at 2 weeks, P < 0.01) and the augmentation pressure decreased from a baseline value of 21 +/- 8 to 11 +/- 7 at 2 h and 10 +/- 5 at 2 weeks, (P < 0.01) following valsartan. Conclusion: The results of our study show that in a group of poorly controlled hypertensives, combining an ATII AT(1) receptor blocker to an ACE inhibitor induced a significant fall in blood pressure, The decrease in blood pressure was accompanied by a decrease in augmentation pressure in the ascending aorta with a greater decrease in the central pulse pressure than in the peripheral, favourably increasing pulse pressure amplification between central and peripheral arteries. This effect on arterial stiffness and amplification suggests that combined angiotensin II blockade by adding an AT(1) receptor blocker to an ACE inhibitor may have more beneficial effects on the blood pressure curve than simple blood pressure reduction.
引用
收藏
页码:541 / 546
页数:6
相关论文
共 35 条
[1]   ARTERIAL STIFFNESS - A NEW CARDIOVASCULAR RISK FACTOR [J].
ARNETT, DK ;
EVANS, GW ;
RILEY, WA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1994, 140 (08) :669-682
[2]   ADDITIVE EFFECTS OF COMBINED ANGIOTENSIN-CONVERTING ENZYME-INHIBITION AND ANGIOTENSIN-II ANTAGONISM ON BLOOD-PRESSURE AND RENIN RELEASE IN SODIUM-DEPLETED NORMOTENSIVES [J].
AZIZI, M ;
CHATELLIER, G ;
GUYENE, TT ;
MURIETAGEOFFROY, D ;
MENARD, J .
CIRCULATION, 1995, 92 (04) :825-834
[3]  
Blantz RC, 1998, WENN GR INT, V74, P57
[4]   DIFFERENT EFFECTS OF FOSINOPRIL AND ATENOLOL ON WAVE REFLECTIONS IN HYPERTENSIVE PATIENTS [J].
CHEN, CH ;
TING, CT ;
LIN, SJ ;
HSU, TL ;
YIN, FCP ;
SIU, CO ;
CHOU, P ;
WANG, SP ;
CHANG, MS .
HYPERTENSION, 1995, 25 (05) :1034-1041
[5]   The Trevor Howell Lecture - Age, arterial stiffness and the endothelium [J].
Cockcroft, JR ;
Wilkinson, IB ;
Webb, DJ .
AGE AND AGEING, 1997, 26 :53-60
[6]   ARTERIAL TONOMETRY - REVIEW AND ANALYSIS [J].
DRZEWIECKI, GM ;
MELBIN, J ;
NOORDERGRAAF, A .
JOURNAL OF BIOMECHANICS, 1983, 16 (02) :141-152
[7]   Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study [J].
Franklin, SS ;
Khan, SA ;
Wong, ND ;
Larson, MG ;
Levy, D .
CIRCULATION, 1999, 100 (04) :354-360
[8]   Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure [J].
Hamroff, G ;
Katz, SD ;
Mancini, D ;
Blaufarb, I ;
Bijou, R ;
Patel, R ;
Jondeau, G ;
Olivari, MT ;
Thomas, S ;
Le Jemtel, TH .
CIRCULATION, 1999, 99 (08) :990-992
[9]   Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril [J].
Holwerda, NJ ;
Fogari, R ;
Angeli, P ;
Porcellati, C ;
Hereng, C ;
OddouStock, P ;
Heath, R ;
Bodin, F .
JOURNAL OF HYPERTENSION, 1996, 14 (09) :1147-1151
[10]  
HUAN CC, 1999, CIRCULATION, V95, P1827